Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
| Status: | Archived |
|---|---|
| Conditions: | Psychiatric, Bipolar Disorder |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder
The purpose of this study is to test the effectiveness and tolerability/safety of
aripiprazole (abilify) in children with subsyndromal symptoms of bipolar disorder who also
have a bipolar parent and other family member with a mood disorder.
This will be a double-blind, placebo-controlled, parallel-arm, randomized clinical trial
that will last up to 12 weeks.
This placebo-controlled portion will be followed by a 6-week open label
extension/stabilization phase. In order to be eligible for participation in the
extension/stabilization phase, subjects must: 1) in the investigator's opinion have had no
dose-limiting side effects likely to be attributable to APZ; 2) participated in the blinded
portion of the clinical trial for a minimum of 4 weeks.
We found this trial at
1
site
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
